Gossamer Bio (NASDAQ:GOSS) Coverage Initiated by Analysts at Chardan Capital

Chardan Capital assumed coverage on shares of Gossamer Bio (NASDAQ:GOSS) in a note issued to investors on Tuesday, Marketbeat reports. The brokerage set a “buy” rating on the stock.

Several other equities research analysts have also issued reports on the company. Wall Street Zen lowered Gossamer Bio from a “hold” rating to a “sell” rating in a research note on Sunday, September 20th. Leerink Partners upgraded Gossamer Bio from a “market perform” rating to an “outperform” rating and set a $80.00 price target on the stock in a report on Tuesday, July 28th. HC Wainwright restated a “buy” rating on shares of Gossamer Bio in a report on Thursday, August 27th. Finally, Weiss Ratings upgraded Gossamer Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday. Five equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, Gossamer Bio has an average rating of “Hold” and an average price target of $256.00.

Gossamer Bio Trading Up 5.2%

GOSS traded up $0.48 on Tuesday, hitting $9.76. The company had a trading volume of 477,946 shares, compared to its average volume of 312,377. Gossamer Bio has a 12-month low of $8.99 and a 12-month high of $309.60. The business’s fifty day simple moving average is $12.25 and its 200 day simple moving average is $17.23.

Institutional Trading of Gossamer Bio

Several institutional investors and hedge funds have recently made changes to their positions in GOSS. Corient Private Wealth LP increased its position in shares of Gossamer Bio by 41.3% during the second quarter. Corient Private Wealth LP now owns 5,632,698 shares of the company’s stock worth $927,000 after acquiring an additional 1,647,315 shares during the period. Bank of America Corp DE purchased a new stake in shares of Gossamer Bio in the second quarter valued at approximately $65,000. Hsbc Holdings PLC boosted its holdings in shares of Gossamer Bio by 1,289.4% in the second quarter. Hsbc Holdings PLC now owns 1,583,118 shares of the company’s stock valued at $267,000 after purchasing an additional 1,469,175 shares during the period. Kalehua Capital Management LLC bought a new position in Gossamer Bio in the first quarter worth approximately $3,363,000. Finally, BlackRock Inc. bought a new position in Gossamer Bio in the second quarter worth approximately $1,262,000. 81.23% of the stock is currently owned by institutional investors.

About Gossamer Bio

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing medicines for patients with disorders involving the immune system, inflammation and fibrosis. The company is headquartered in San Diego, California, and primarily operates through the development of its proprietary drug candidates and strategic collaborations.

Gossamer’s lead product candidate is seralutinib, an inhaled tyrosine kinase inhibitor designed to target pathways associated with pulmonary vascular remodeling.